Germany, July 6 -- BASF and Bota Biosciences jointly announced the market launch of BASF's SkinNexus (TM) Collag3n. This 100% human-identical recombinant Collagen III fragment was developed in collaboration between the two companies and is being commercialized by BASF for the personal care market. The ingredient made its global debut at in-cosmetics Global in April 2026.SkinNexus (TM) Collag3n merges Bota's world-leading Physical AI-driven biofoundry capabilities with BASF's premier technology for cosmetic actives. Drawing on their combined expertise in AI, synthetic biology, skin science, and biomanufacturing, Bota and BASF screened over 2,000 collagen fragments. Candidate evaluation ran in parallel with industrial feasibility validation. ...